Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587029677> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2587029677 endingPage "ix28" @default.
- W2587029677 startingPage "ix28" @default.
- W2587029677 abstract "Background The first ever Tomotherapy-H system in India became operational in Feb 2016 in our hospital, Health care global enterprises, a tertiary level cancer care centre. In order to implement Tomotherapy as a routine technique to treat breast cancers we under took dosimetric comparison of helical Tomotherapy plans and five field forward planning intensity modulated radiotherapy (IMRT) plans. Methods We compared the Helical Tomotherapy plans with IMRT plans of the first 10 patients with early breast cancer who underwent adjuvant RT using helical Tomotherapy technique in our centre between February 2016 and June 2016. The treatment planning objectives were to cover 95% of the planning target volume (PTV) using a 95% isodose (V95 >/= 95%), with a minimum of 90% isodose covering 100% of PTV (V100 >/= 90%) and no more than 10% ofPTV to receive 110% (V110 <10%). The heart and lungs were contoured as organs at risk (OAR) and doses received were recorded in both the planning techniques. Results All patients were females with four right and six left sided cancers. Seven patients had undergone breast conserving surgery and three had mastectomy. When we compared the forward planning IMRT plans with Helical Tomotherapy plans, we found thattheadvantageofusingHelicalTomotherapyincludedsignificantlybettercoverage forV95(p<0.000),V100(p<0.000)andmedianV110was0.06%and0.14%in Helical Tomotherapy and IMRT plans respectively. Helical Tomotherapy plans had lower dose to ipsilateral lung (V35 P < 0.01) and lower median dose to the heart (Tomotherapy=8.2andIMRT=9Gy).Therewasimprovedcoverageoftheplanning target volume, including the regional nodes, without any field junction problems. None ofthepatientshadanymorethangrade1 skintoxicityandgrade1 oesophagitis. Conclusions Helical Tomotherapy, compared to forward planning IMRT for breast cancer treatment, demonstrated better target coverage and sparing ofOARs. The treatment was well tolerated with minimal toxicity. Long term toxicity is yet to be established by continued follow up ofthese patients in late side effects clinics. Legal entity responsible for the study Health Care Global Enterprises Funding Health Care Global Enterprises Disclosure All authors have declared no conflicts ofinterest." @default.
- W2587029677 created "2017-02-17" @default.
- W2587029677 creator A5000574277 @default.
- W2587029677 creator A5007262103 @default.
- W2587029677 creator A5011143459 @default.
- W2587029677 creator A5040152539 @default.
- W2587029677 creator A5047126922 @default.
- W2587029677 creator A5061984861 @default.
- W2587029677 date "2016-12-01" @default.
- W2587029677 modified "2023-09-27" @default.
- W2587029677 title "95P Radiotherapy (RT) for breast cancer patients- clinical implementation of the first ever Tomotherapy-H in a tertiary cancer centre in India" @default.
- W2587029677 doi "https://doi.org/10.1016/s0923-7534(21)00255-6" @default.
- W2587029677 hasPublicationYear "2016" @default.
- W2587029677 type Work @default.
- W2587029677 sameAs 2587029677 @default.
- W2587029677 citedByCount "0" @default.
- W2587029677 crossrefType "journal-article" @default.
- W2587029677 hasAuthorship W2587029677A5000574277 @default.
- W2587029677 hasAuthorship W2587029677A5007262103 @default.
- W2587029677 hasAuthorship W2587029677A5011143459 @default.
- W2587029677 hasAuthorship W2587029677A5040152539 @default.
- W2587029677 hasAuthorship W2587029677A5047126922 @default.
- W2587029677 hasAuthorship W2587029677A5061984861 @default.
- W2587029677 hasBestOaLocation W25870296771 @default.
- W2587029677 hasConcept C121608353 @default.
- W2587029677 hasConcept C126322002 @default.
- W2587029677 hasConcept C126838900 @default.
- W2587029677 hasConcept C141071460 @default.
- W2587029677 hasConcept C201645570 @default.
- W2587029677 hasConcept C2776713427 @default.
- W2587029677 hasConcept C2777757722 @default.
- W2587029677 hasConcept C2989005 @default.
- W2587029677 hasConcept C2991842025 @default.
- W2587029677 hasConcept C3018454096 @default.
- W2587029677 hasConcept C509974204 @default.
- W2587029677 hasConcept C530470458 @default.
- W2587029677 hasConcept C71924100 @default.
- W2587029677 hasConceptScore W2587029677C121608353 @default.
- W2587029677 hasConceptScore W2587029677C126322002 @default.
- W2587029677 hasConceptScore W2587029677C126838900 @default.
- W2587029677 hasConceptScore W2587029677C141071460 @default.
- W2587029677 hasConceptScore W2587029677C201645570 @default.
- W2587029677 hasConceptScore W2587029677C2776713427 @default.
- W2587029677 hasConceptScore W2587029677C2777757722 @default.
- W2587029677 hasConceptScore W2587029677C2989005 @default.
- W2587029677 hasConceptScore W2587029677C2991842025 @default.
- W2587029677 hasConceptScore W2587029677C3018454096 @default.
- W2587029677 hasConceptScore W2587029677C509974204 @default.
- W2587029677 hasConceptScore W2587029677C530470458 @default.
- W2587029677 hasConceptScore W2587029677C71924100 @default.
- W2587029677 hasLocation W25870296771 @default.
- W2587029677 hasOpenAccess W2587029677 @default.
- W2587029677 hasPrimaryLocation W25870296771 @default.
- W2587029677 hasRelatedWork W106094071 @default.
- W2587029677 hasRelatedWork W1967380069 @default.
- W2587029677 hasRelatedWork W2035963962 @default.
- W2587029677 hasRelatedWork W2106175699 @default.
- W2587029677 hasRelatedWork W2329992540 @default.
- W2587029677 hasRelatedWork W2382317557 @default.
- W2587029677 hasRelatedWork W2466949046 @default.
- W2587029677 hasRelatedWork W2618285609 @default.
- W2587029677 hasRelatedWork W4206913854 @default.
- W2587029677 hasRelatedWork W4307146680 @default.
- W2587029677 hasVolume "27" @default.
- W2587029677 isParatext "false" @default.
- W2587029677 isRetracted "false" @default.
- W2587029677 magId "2587029677" @default.
- W2587029677 workType "article" @default.